{"filings":[{"id":860934,"accession_number":"0001493152-26-027266","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-06-04T20:05:28+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve Lipocine stock plan amendment; authorized shares raised to 1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Sixth Amended and Restated 2014 Stock Plan on June 3, 2026.","Plan increases individual award limit from 25,000 to 100,000 shares.","Authorized shares increased by 400,000, from 600,000 to 1,000,000 shares.","Four directors elected to one-year terms: Dr. Mahesh V. Patel, John W. Higuchi, Dr. Jill M. Jene, Dr. Richard Dana Ono.","Ratification of Tanner LLC as independent auditor for FY 2026 and advisory vote on executive compensation both approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":843877,"accession_number":"0001493152-26-027209","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-06-04T13:00:32+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine to host virtual KOL event on LPCN 1154 for postpartum depression on June 12, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Virtual KOL event focused on unmet needs in postpartum depression and clinical profile of LPCN 1154 (oral brexanolone).","Event scheduled for June 12, 2026 at 11:00 AM ET; advance registration required.","LPCN 1154 Phase 3 trial showed efficacy in subgroup analysis excluding outlier site; 100% dosing completion.","PPD affects ~1 in 5 U.S. women; annual economic burden estimated at $14.2 billion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":669917,"accession_number":"0001493152-26-025270","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-05-26T21:08:04+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine Presents Phase 3 Data for LPCN 1154 (Oral Brexanolone) for Postpartum Depression at ASCP","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["May 26, 2026: Company highlighted results from placebo-controlled Phase 3 trial of LPCN 1154 for PPD at ASCP Annual Meeting.","The presentation and poster are furnished as exhibits but not included in the 8-K text; specific efficacy and safety endpoints are unconfirmed.","LPCN 1154 is an oral rapid-acting neuroactive steroid (brexanolone); this readout supports potential label expansion.","Stock impact uncertain without actual data; materiality depends on trial outcomes not disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":509357,"accession_number":"0001493152-26-024365","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-05-19T13:00:16+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine LPCN 1154 Phase 3 data accepted for oral presentation at 2026 ASCP meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 data for LPCN 1154 (oral brexanolone) for postpartum depression accepted for oral and poster presentation at ASCP Annual Meeting May 26-29, 2026 in Miami, FL.","Oral presentation by Benjamin Bruno, PhD, VP Clinical Development, on May 26, 2026 at 3:20 PM ET; poster session on May 27.","LPCN 1154 is an oral non-SSRI neuroactive steroid that acts as a positive allosteric modulator of GABAA receptors.","Potential for acute stabilization of PPD symptoms with low CNS depressant side effects, no intensive monitoring required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":483076,"accession_number":"0001493152-26-024097","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-05-18T13:00:24+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine to present at A.G.P. Annual Virtual Healthcare Showcase on May 20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fireside chat scheduled for 3:00 PM ET on Wednesday, May 20, 2026.","Investors can register and view the chat via the conference platform.","Lipocine's pipeline includes candidates for postpartum depression, epilepsy, and obesity.","No financial results or business updates were disclosed in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93521,"accession_number":"0001493152-26-021712","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine updates corporate presentation; no material new information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company updated its corporate presentation, filed as Exhibit 99.1 to this 8-K.","Presentation is used for meetings with investors, analysts, and others.","No financial results, guidance changes, or material events were announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93520,"accession_number":"0001493152-26-021638","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lipocine misses Q1 EPS estimates; LPCN 1154 PPD Phase 3 fails primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.7M ($0.52/share) vs $1.9M loss ($0.35) in Q1 2025; cash $24.7M.","Phase 3 trial of LPCN 1154 for postpartum depression missed primary endpoint; HAM-D reduction vs placebo not significant at hour 60.","LPCN 1154 well-tolerated; no serious AEs, sedation, or loss of consciousness; post hoc significance in patients with psychiatric history (n=54).","Company applied for breakthrough/fast track designations for LPCN 1154; evaluating validation study or strategic options.","TLANDO royalty revenue $119K in Q1 2026 versus $94K in prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":119397.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93519,"accession_number":"0001493152-26-018299","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lipocine director Spyros Papapetropoulos resigns; R. Dana Ono appointed Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Spyros Papapetropoulos resigned from Lipocine Board effective April 16, 2026, citing competing commitments and differing views on strategic direction.","R. Dana Ono appointed Chairman and Lead Independent Director on April 20, 2026, replacing Papapetropoulos.","Papapetropoulos had served on the Board since 2022 and was Chairman prior to resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93518,"accession_number":"0001493152-26-014835","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine updates corporate presentation; no material new details disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed an 8-K on April 2, 2026, stating it updated its corporate presentation used with investors.","Presentation filed as Exhibit 99.1 but no specific content or changes were described in the filing text.","No financial or operational metrics, guidance, or business developments were reported.","Filing appears routine and lacks substantive information for investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93517,"accession_number":"0001493152-26-014834","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine's LPCN 1154 Phase 3 PPD trial misses primary endpoint; post hoc signals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint not met: no statistically significant HAM-D17 reduction vs placebo at hour 60 in full population (N=90).","Post hoc analysis of participants with psychiatric history (n=54) showed nominal significant reductions from hour 12 through day 30.","LPCN 1154 was well tolerated; no SAEs, excessive sedation, or treatment-related discontinuations reported.","Company evaluating all options, including further LPCN 1154 development, strategic transactions, and FDA designations (breakthrough/fast track applied)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105213,"accession_number":"0001493152-26-009428","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lipocine reports FY2025 net loss of $9.6M; cash $14.9M; PPD Phase 3 topline due April 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.6M ($1.69/diluted) vs $8K net income in FY2024; revenue fell to $2.0M from $11.2M.","Cash and equivalents $14.9M at Dec 31, 2025, increased to $24.7M post-ATM offering in Q1 2026.","Phase 3 study of LPCN 1154 (PPD) completed last patient visit; topline data expected early April 2026.","R&D expenses rose to $8.6M from $7.4M on higher clinical study costs; G&A down to $3.8M.","Company plans 505(b)(2) NDA submission for LPCN 1154 in mid-2026 if Phase 3 successful."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105212,"accession_number":"0001493152-26-008852","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine files $50M ATM equity facility with A.G.P./Alliance Global Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on Feb 26, 2026 for sale of up to $50M common stock via ATM.","Sales agreement originally dated April 26, 2024 with A.G.P./Alliance Global Partners.","Legal opinion on share validity from Dorsey & Whitney LLP included as Exhibit 5.1.","No specific use of proceeds disclosed in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105211,"accession_number":"0001493152-26-007288","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine updates corporate presentation; no material new details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed an updated corporate presentation under Item 8.01.","No specific financial or operational changes provided in the filing.","The presentation is used for meetings with investors and analysts.","No material events, guidance, or data points were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105210,"accession_number":"0001493152-26-007287","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Lipocine completes last patient last visit in Phase 3 trial of LPCN 1154 for PPD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Last patient completed final visit in pivotal Phase 3 trial of LPCN 1154 (oral brexanolone) for postpartum depression.","Trial enrolled 90 patients with severe PPD (average baseline HAM-D 28.3); positive safety profile with no discontinuations.","Company expects Phase 3 data to support 505(b)(2) NDA submission for LPCN 1154 in 2026.","Preliminary cash and equivalents ~$19M as of Jan 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105209,"accession_number":"0001493152-26-002785","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine completes Phase 3 enrollment for oral brexanolone in postpartum depression; topline data due Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["90 patients randomized in double-blind, placebo-controlled Phase 3 trial of LPCN 1154 (oral brexanolone) for PPD.","Safety profile favorable: no discontinuations, excessive sedation, loss of consciousness, or drug-related SAEs.","Outpatient setting, no medical monitoring required; study incorporates FDA feedback.","Topline efficacy and safety results expected early Q2 2026; NDA submission planned for 2026.","LPCN 1154 could become first-line treatment for severe PPD, including elevated suicide risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105208,"accession_number":"0001493152-26-001864","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine updates corporate presentation; no material details in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Lipocine updated its corporate presentation used in investor meetings.","Filing does not describe specific changes from previous presentation.","No new financial projections, pipeline milestones, or guidance changes announced.","Presentation available as Exhibit 99.1; review may reveal material updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105207,"accession_number":"0001493152-26-001254","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine: Phase 3 PPD trial passes second DSMB safety review; topline data due Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB reviewed safety data from 82 randomized patients; recommended trial continue without modification.","No drug discontinuations, excessive sedation, loss of consciousness, or drug-related SAEs reported.","Study no longer screening new participants; still enrolling eligible patients.","Topline safety and efficacy results expected early Q2 2026; data to support NDA submission.","CEO cites confidence in safety profile; potential for new treatment paradigm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121465,"accession_number":"0001493152-25-027914","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine's PPD Phase 3 study hits 80% enrollment; DSMB review in Jan 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["66 of 80 planned participants randomized in Phase 3 trial of LPCN 1154 for postpartum depression.","Second independent DSMB review planned for mid-January 2026; first review recommended continuation.","Topline results expected Q2 2026; NDA submission under 505(b)(2) planned for 2026.","Study conducted entirely outpatient; no medical monitoring required per FDA feedback."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121464,"accession_number":"0001493152-25-027744","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jeffrey Fink resigns from Lipocine Board effective Jan 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Fink informed the Board on Dec 12, 2025 of his resignation effective Jan 1, 2026 for personal reasons.","Resignation not due to any disagreement with the Company on any matter.","Board intends to conduct a search for a new director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121463,"accession_number":"0001493152-25-027273","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine presents LPCN 2101 posters at AES meeting; no specific data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Posters for LPCN 2101, a GABA A receptor PAM candidate for epilepsy, presented at AES Annual Meeting Dec 5-9, 2025.","Poster 99.1 covers clinical PK and tolerability; Poster 99.2 covers oral toxicokinetics for women with epilepsy.","No efficacy, safety, or numerical results included in the filing; exhibits referenced but not detailed.","LPCN 2101 is a novel oral neuroactive steroid anti-seizure medication candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121462,"accession_number":"0001493152-25-024012","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine files updated corporate presentation; no material facts disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed an updated investor presentation as Exhibit 99.1 to its November 18, 2025 8-K.","No financial results, guidance, or specific operational metrics were described in the filing.","The presentation is used in meetings with investors and analysts; no new events announced.","Filing contains only procedural updates under Item 8.01; no material news identifiable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121461,"accession_number":"0001493152-25-024011","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine reports promising interim safety for LPCN 1154 in Phase 3 PPD trial; topline Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB review after one-third of planned 80 participants (n=30) recommended continuation as planned without modification.","47 participants completed dosing with no dose reductions, discontinuations, drug-related SAEs, loss of consciousness, or excessive sedation.","Topline results on track for Q2 2026; second DSMB and safety update targeted early Q1 2026.","Phase 3 data expected to support 505(b)(2) NDA submission for LPCN 1154 later in 2026.","Trial conducted entirely in outpatient setting per FDA feedback; 19 U.S. clinical sites participating."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121460,"accession_number":"0001493152-25-021008","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lipocine Q3 net loss widens to $3.2M; cash drops to $15.1M; PPD trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.2M ($0.59/sh) vs $2.2M loss ($0.44/sh) in Q3 2024.","Cash & investments $15.1M at Sep 30, 2025, down from $21.6M at Dec 31, 2024.","R&D spend $2.7M (+69% YoY) driven by LPCN 1154 Phase 3 PPD trial; top-line data expected Q2 2026.","TLANDO royalty revenue $115k; nine-month license revenue $500k vs $7.5M prior year from Verity deal.","LPCN 2101 abstracts accepted for AES meeting Dec 5-9; exploring partnerships for multiple assets."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":831287.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121459,"accession_number":"0001493152-25-020677","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine presents LPCN 2401 Phase 2 data at ObesityWeek showing improved body composition and liver health","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In Phase 2 trial, LPCN 2401 increased lean mass, reduced fat mass, and improved fat-to-lean ratio vs placebo at 20 and 36 weeks.","Treatment with LPCN 2401 showed rapid reductions in liver fat content and liver injury markers (ALT, AST) starting at 4-8 weeks.","MRI-PDFF demonstrated significant reductions in liver fat at 12 weeks, maintained through week 36.","LPCN 2401 was well tolerated with no concerning safety signals observed through 72 weeks of exposure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138132,"accession_number":"0001493152-25-016210","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine LPCN 1154 Phase 3 PPD trial: 1/3 randomized; topline 2Q26; DSMB review 4Q25","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One-third of planned patients randomized in LPCN 1154 Phase 3 trial for postpartum depression.","Topline results expected in second quarter 2026.","Independent DSMB safety review planned for fourth quarter 2025; update post-DSMB.","Trial conducted entirely outpatient; no medical monitoring by HCP required per FDA feedback.","CEO Mahesh Patel states LPCN 1154 can become standard of care; 505(b)(2) NDA submission targeted in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138131,"accession_number":"0001493152-25-015081","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine delays LPCN 2401 POC study, seeks FDA clarity on endpoints","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received IND clearance for LPCN 2401 as adjunct to GLP-1 therapy.","Seeking regulatory clarity on POC study endpoints, including functional loss.","POC study on hold pending FDA feedback; corporate presentation updated.","No timeline provided for resolution; development path uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138130,"accession_number":"0001493152-25-012740","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine to Present at H.C. Wainwright Conference Sept 8-10, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company management will present and hold 1x1 meetings at H.C. Wainwright 27th Annual Global Investment Conference in New York.","Conference runs September 8-10, 2025; presentation available from 7:00 a.m. EDT on Sept 5.","Lipocine's pipeline includes LPCN 1154 (postpartum depression), LPCN 2101 (epilepsy), LPCN 2203 (essential tremor), and others.","TLANDO (testosterone undecanoate) is FDA-approved for hypogonadism; company exploring partnerships for several candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138129,"accession_number":"0001493152-25-012698","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine to present at H.C. Wainwright conference; no new material updates filed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presenting at H.C. Wainwright 27th Annual Global Investor Conference, Sept 8-10, 2025, in NYC.","No earnings, guidance, or material business developments announced in this filing.","Investors should review the conference presentation for any business updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138128,"accession_number":"0001493152-25-012325","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine announces LPCN 2101 abstracts accepted for AES 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two LPCN 2101 abstracts accepted for poster presentation at AES 2025 (Dec 5-9, Atlanta).","Abstracts cover oral toxicokinetics and clinical pharmacokinetics/tolerability of LPCN 2101.","LPCN 2101 is a GABA-A receptor modulating neuroactive steroid for potential treatment of epilepsy.","Data remain embargoed until November 24, 2025, per AES policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138127,"accession_number":"0001493152-25-011589","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lipocine Q2 net loss narrows to $2.2M; Phase 3 PPD study underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.2M ($0.41/diluted share) vs $3.1M loss year ago; cash $17.9M at quarter end.","LPCN 1154 Phase 3 pivotal trial for postpartum depression dosing patients; topline Q2 2026, NDA mid-2026.","LPCN 2401 Phase 2 proof-of-concept study in obesity planned, first patient dosing target Q3 2025.","TLANDO NDS filed in Canada by Verity Pharma in June; Brazil license deal with Aché in April.","Total revenue $623K (Q2) vs $90K year ago, including $500K license revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":716713.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138126,"accession_number":"0001641172-25-018333","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine hosts KOL event on LPCN 1154 (BRLIZIO™) for postpartum depression","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Virtual key opinion leader event held July 9, 2025, for LPCN 1154 (BRLIZIO™).","Drug candidate targets postpartum depression; presentation replay on corporate website.","No clinical data or financial guidance disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138125,"accession_number":"0001641172-25-017497","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine updates corporate presentation; no material details available","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Routine update to investor presentation; no new financial guidance or product data provided.","Presentation filed as Exhibit 99.1 on July 2, 2025; content not summarized in filing.","No earnings, guidance, or clinical updates indicated; investors should review the full deck."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155564,"accession_number":"0001641172-25-016589","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine doses first patient in Phase 3 trial for oral brexanolone (LPCN 1154) in postpartum depression","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in pivotal Phase 3 trial of LPCN 1154 (oral brexanolone) for postpartum depression; top line data expected Q2 2026.","Trial is outpatient with no medical monitoring required; 48-hour treatment regimen, randomized, blinded vs placebo in women ≥15 with severe PPD.","Primary endpoint is change from baseline in HAM-D scale; NDA submission targeted for mid-2026 based on Phase 3 data.","Virtual investor event on LPCN 1154 scheduled for July 9, 2025 at 11:00 AM ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155563,"accession_number":"0001641172-25-016014","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine to host R&D event July 9, 2025 on LPCN 1154 for postpartum depression; Phase 3 data Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Virtual R&D investor event on July 9, 2025 at 11 AM ET to discuss LPCN 1154 (BRLIZIO) for postpartum depression (PPD).","Phase 3 registrational study recently initiated; top-line data expected in Q2 2026.","Event features Dr. Kristina Deligiannidis; includes clinical, regulatory, and development updates with Q&A.","LPCN 1154 is an oral brexanolone formulation targeting rapid symptom relief with 48-hour outpatient treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155562,"accession_number":"0001641172-25-014224","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine's partner Verity Pharma files New Drug Submission for TLANDO in Canada","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Over 700,000 annual TRT prescriptions in Canada, representing large opportunity.","TLANDO is the first US FDA-approved oral TRT without dose titration.","Exclusive license with Verity signed Jan 2024; NDS covers Canada.","CEO Mahesh Patel says if approved, TLANDO could drive significant market gains.","About 50% of Canadian TRT patients have private insurance coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155561,"accession_number":"0001641172-25-013603","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Lipocine shareholders approve reduction in authorized shares from 200M to 75M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Authorized common stock reduced from 200M to 75M shares; Certificate of Amendment filed June 4, 2025.","All six director nominees elected: Dr. Mahesh V. Patel, Jeffrey A. Fink, John W. Higuchi, Dr. Jill M. Jene, Dr. Richard Dana Ono, Dr. Spyros Papapetropoulos.","Tanner LLC ratified as independent auditor for FY 2025 with 2,817,444 votes for, 86,618 against.","Non-binding advisory vote on executive compensation passed: 926,497 for, 121,032 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155560,"accession_number":"0001641172-25-012000","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine's LPCN 1148 for cirrhosis highlighted in Hepatology journal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LPCN 1148 for men with cirrhosis featured in 'Hepatology Highlights' in June 2025 edition of Hepatology.","Article contributed by Dr. Kevin Harris of Mayo Clinic; Phase 2 results published in same issue.","FDA granted fast track designation for LPCN 1148 as treatment for sarcopenia in decompensated cirrhosis.","CEO Mahesh Patel highlighted growing recognition of LPCN 1148's potential to improve cirrhosis outcomes.","Company is exploring partnering opportunities for LPCN 1148."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155559,"accession_number":"0001641172-25-010118","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine to present at A.G.P. Annual Healthcare Company Showcase on May 21, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Presentation at 4:00 pm ET on May 21, 2025; virtual event hosted by A.G.P.","Webcast and replay accessible via Lipocine's investor website.","No new clinical data or financial results disclosed; routine investor conference participation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155558,"accession_number":"0001641172-25-009772","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine updates corporate presentation; no financial results or material news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation filed as Exhibit 99.1; no specific changes quantified.","No earnings, guidance, or operational updates provided in the filing.","Routine update to investor materials; low materiality for shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155557,"accession_number":"0001641172-25-009179","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine Q1 net loss $1.9M; starts Phase 3 for PPD drug LPCN 1154","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.9M ($0.35 diluted share) vs net income $3.5M ($0.66) in Q1 2024.","Cash and equivalents $19.7M at March 31, 2025, down from $21.6M at Dec 31, 2024.","Initiated outpatient Phase 3 study of LPCN 1154 (oral brexanolone) for postpartum depression; first patient dosing expected Q2 2025.","Entered TLANDO license agreement for Brazil with Aché; exploring partnerships for LPCN 1154 and LPCN 2401.","Plans proof-of-concept study for LPCN 2401 as adjunct to GLP-1 therapies, targeting elderly patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":93864.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155556,"accession_number":"0001641172-25-008766","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine licenses TLANDO in Brazil; oral testosterone market grew 34% CAGR 2019-2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license and supply agreement with Aché Laboratórios for TLANDO in Brazil.","Lipocine receives upfront payment, plus regulatory milestones and royalties on net sales.","Aché is responsible for regulatory submission and approval in Brazil.","No oral testosterone therapy is currently registered in Brazil; market CAGR 34% 2019-2023.","TLANDO is FDA-approved for testosterone replacement therapy in adult males with hypogonadism."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155555,"accession_number":"0001641172-25-002581","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine updates corporate presentation; no material news","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation refreshed for investor and analyst meetings.","No financial results, guidance, or operational updates announced in filing.","Presentation content not disclosed in the text; investors should review Exhibit 99.1 for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174052,"accession_number":"0001641172-25-000693","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine initiates Phase 3 outpatient PPD trial of LPCN 1154; dosing expected Q2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiation of randomized, blinded, placebo-controlled Phase 3 trial of LPCN 1154 for PPD; first patient dosing expected Q2 2025.","48-hour at-home self-administration regimen based on FDA protocol feedback.","Primary endpoint: change from baseline in HAM-D; secondary endpoints include MADRS and HAM-A.","Trial size powered based on observed effect of injectable brexanolone (Zulresso)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174051,"accession_number":"0001493152-25-010149","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine reports near-breakeven 2024; FDA requires Phase 3 for oral brexanolone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of ~$8,400 vs net loss of $16.4M in 2023; revenue of $11.2M from license/royalty fees.","Cash and securities $21.6M at Dec 31, 2024, vs $22.0M at Dec 31, 2023.","FDA meeting for LPCN 1154 requires safety/efficacy study for NDA; Phase 3 start expected Q2 2025.","TLANDO license agreements generated $10M in 2024; Verity milestones up to $259M plus tiered royalties.","FDA removed Boxed Warning on cardiovascular risk for testosterone products in Feb 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174050,"accession_number":"0001493152-25-009955","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA removes Boxed Warning for testosterone products after TRAVERSE trial benefits Lipocine","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA removes Boxed Warning on cardiovascular risk for all testosterone products based on TRAVERSE trial.","Label changes include adding TRAVERSE results and retaining Limitation of Use for age-related hypogonadism.","FDA requires product-specific blood pressure information from ABPM studies on all testosterone labels.","Lipocine CEO says label changes beneficial to approved TLANDO and pipeline candidates for obesity and liver disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174049,"accession_number":"0001493152-25-005809","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine updates corporate presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an updated corporate presentation used for investor meetings.","No financial results, guidance, or material events announced.","Presentation filed as Exhibit 99.1 with no specific details provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174048,"accession_number":"0001493152-25-005108","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA requires Phase 3 efficacy/safety study for Lipocine's LPCN 1154 in PPD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA advised that an efficacy and safety study in target population is needed for 505(b)(2) NDA submission, beyond prior PK bridge data.","Lipocine is now planning a Phase 3 safety and efficacy study for oral LPCN 1154 (brexanolone) for postpartum depression.","CEO stated study could support product labeling, exclusivity for 48-hour oral treatment, and also investigate anxiety disorders.","Previous expectations were to discuss NDA package in Q1 2025; new guidance adds clinical trial requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174047,"accession_number":"0001493152-25-001841","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocine updates corporate investor presentation; no specific changes disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed updated corporate presentation as Exhibit 99.1 used with investors and analysts.","No financial data, milestones, or guidance changes included in the 8-K text.","Presentation content not provided in the filing excerpt; materiality cannot be assessed.","Ticker LPCN; common stock listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191009,"accession_number":"0001493152-24-050346","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Fast Track Designation to Lipocine for LPCN 1148 in decompensated cirrhosis sarcopenia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Fast Track Designation granted to LPCN 1148 for sarcopenia in decompensated cirrhosis, an unmet medical need.","LPCN 1148 is an oral prodrug of bioidentical testosterone; POC Phase 2 study showed improved sarcopenia and clinical outcomes.","Fast Track benefits include more frequent FDA meetings, eligibility for Accelerated Approval, Priority Review, and Rolling Review.","Over 382,000 U.S. patients with decompensated cirrhosis; no FDA-approved treatments for associated sarcopenia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191008,"accession_number":"0001493152-24-049874","cik":1535955,"company_name":"Lipocine Inc.","ticker":"LPCN","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lipocinc updates corporate presentation for investor meetings","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed an updated corporate presentation as Exhibit 99.1 to 8-K.","Presentation is used in meetings with investors, analysts, and other stakeholders.","No specific financial or operational changes were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":18796897.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-12-13T23:59:59+00:00|191008"}